Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.

ABSTRACT:

Background

Prior studies regarding use of Aromatase inhibitors (AIs) and risk for cardiovascular disease (CVD) have shown conflicting results. This retrospective cohort study aimed to investigate whether AIs use affects risk for CVD events in postmenopausal breast cancer survivors.

Methods

Using a retrospective cohort study design, four CVD outcomes; heart failure or cardiomyopathy, arrhythmia, acute ischemic heart disease and ischemic stroke or Transient Ischemic Attack were compared with uni- and multivariate Cox regression analyses according to exposure to endocrine therapy (use of AI, tamoxifen or AI/tamoxifen sequentially) or no endocrine therapy.

Results

In total 15815 postmenopausal women, surgically treated to early breast cancer during 2006-2012, were include

SUBMITTER: Sund M 

PROVIDER: S-EPMC8281646 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature